PT  - JOURNAL ARTICLE
AU  - E Anne MacGregor
AU  - John Guillebaud
TI  - The 7-day contraceptive hormone-free interval should be consigned to history
AID  - 10.1136/bmjsrh-2017-200036
DP  - 2018 Jul 01
TA  - BMJ Sexual & Reproductive Health
PG  - 214--220
VI  - 44
IP  - 3
4099  - http://jfprhc.bmj.com/content/44/3/214.short
4100  - http://jfprhc.bmj.com/content/44/3/214.full
SO  - BMJ Sex Reprod Health2018 Jul 01; 44
AB  - Aim This review summarises the available data on the disadvantages of the 7-day contraceptive-free interval (CFI) of combined oral contraceptives (COCs), in contrast to shorter CFIs or continuous use – including flexible regimens – and provides recommendations for practice.Methods Relevant papers were identified by Medline and PubMed. The final reference list was generated on the basis of relevance to the review, with priority given to systematic reviews and randomised controlled trials.Results There is considerable inter- and intra-individual variation in the absorption and metabolism of COCs. Even with perfect use, the loss of endocrine suppression during the standard 7-day CFI allows follicular development with the risk of escape ovulation in a vulnerable minority. This risk increases in typical users whenever the CFI is prolonged: late restarts are a common reason for pill omissions. Shortening or eliminating the CFI improves contraceptive efficacy using the lowest doses available, without evidence to date of compromised safety.Conclusions There is no scientific evidence to support a 7-day CFI and it should be replaced either by a continuous flexible regimen, or extended regimens with a shortened CFI, prescribed first-line. In women preferring a monthly ‘bleed’, a 4-day CFI similarly provides a greater safety margin when pills are omitted.